Galena Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Its development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including cancer immunotherapy programs led by NeuVax (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase III clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302.